Elevated expression of CDCP1 is associated with poor overall survival of patients with cancer of the breast 18-20, colorectum 21, kidney 22, lung 23, ovary 13,24 and pancreas 25 while a potential protective role has been recently identified in prostate cancer 7. Here, CDCP1 is linked to breast carcinoma.